Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GFH018 and Toripalimab with chemoradiotherapy in stage III NSCLC
NCT05386888Phase 2Completed
- Sponsor
- GenFleet Therapeutics
- Start
- Sep 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gfh018 in non-small cell lung cancer (NSCLC), sponsored by GenFleet Therapeutics. Primary endpoint: Objective Response Rate at 28 months. Started Sep 2022; status: completed.
02
Drugs
gfh018
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05386888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05386888.